A. Patel

Inflammation and tumor progression: signaling pathways and targeted intervention

TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer

Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy

TIGIT in cancer immunotherapy

Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).